Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (<i<p</i< = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. <b<Trial Registration</b<<b<ClinicalTrials.gov Identifier (NCT04730856).</b< Edura-CT registration number: 2020-004279-42..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 11(2022), 19, p 5632 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nuria Muñoz-Rivas [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3390/jcm11195632 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ021329214 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ021329214 | ||
| 003 | DE-627 | ||
| 005 | 20240414184506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11195632 |2 doi | |
| 035 | |a (DE-627)DOAJ021329214 | ||
| 035 | |a (DE-599)DOAJaabebeeae43b4fe2a6575cfe077a9abf | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Nuria Muñoz-Rivas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (<i<p</i< = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. <b<Trial Registration</b<<b<ClinicalTrials.gov Identifier (NCT04730856).</b< Edura-CT registration number: 2020-004279-42. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a pulmonary embolism | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a respiratory insufficiency | |
| 650 | 4 | |a low-molecular-weight heparin | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Jesús Aibar |e verfasserin |4 aut | |
| 700 | 0 | |a Cristina Gabara-Xancó |e verfasserin |4 aut | |
| 700 | 0 | |a Ángela Trueba-Vicente |e verfasserin |4 aut | |
| 700 | 0 | |a Ana Urbelz-Pérez |e verfasserin |4 aut | |
| 700 | 0 | |a Vicente Gómez-Del Olmo |e verfasserin |4 aut | |
| 700 | 0 | |a Pablo Demelo-Rodríguez |e verfasserin |4 aut | |
| 700 | 0 | |a Alberto Rivera-Gallego |e verfasserin |4 aut | |
| 700 | 0 | |a Pau Bosch-Nicolau |e verfasserin |4 aut | |
| 700 | 0 | |a Montserrat Perez-Pinar |e verfasserin |4 aut | |
| 700 | 0 | |a Mónica Rios-Prego |e verfasserin |4 aut | |
| 700 | 0 | |a Olga Madridano-Cobo |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Ramos-Alonso |e verfasserin |4 aut | |
| 700 | 0 | |a Jesús Alonso-Carrillo |e verfasserin |4 aut | |
| 700 | 0 | |a Iria Francisco-Albelsa |e verfasserin |4 aut | |
| 700 | 0 | |a Edelmira Martí-Saez |e verfasserin |4 aut | |
| 700 | 0 | |a Ana Maestre-Peiró |e verfasserin |4 aut | |
| 700 | 0 | |a Manuel Méndez-Bailón |e verfasserin |4 aut | |
| 700 | 0 | |a José Ángel Hernández-Rivas |e verfasserin |4 aut | |
| 700 | 0 | |a Juan Torres-Macho |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 11(2022), 19, p 5632 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:19, p 5632 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm11195632 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/aabebeeae43b4fe2a6575cfe077a9abf |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/11/19/5632 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 19, p 5632 | ||